Merger, Contingent Value Rights Agreement (Details) |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2022
Milestone
|
Nov. 05, 2020
Milestone
Right
|
|
| Contingent Value Rights Agreement [Abstract] | ||
| Contingent value rights payment period | 15 years | |
| Sum of cash consideration paid by a third party | 75.00% | |
| Parent IP deal period | 10 years | |
| Number of milestones accrued | 0 | 0 |
| Number of potential milestones | 0 | 0 |
| Rexahn [Member] | ||
| Contingent Value Rights Agreement [Abstract] | ||
| Number of contingent value right received per common stock | Right | 1 | |
| Rexahn [Member] | BioSense Global LLC [Member] | ||
| Contingent Value Rights Agreement [Abstract] | ||
| Percentage of payments received by Rexahn or its affiliates | 90.00% | |
| Rexahn [Member] | Zhejiang HaiChang Biotechnology Co., Ltd [Member] | ||
| Contingent Value Rights Agreement [Abstract] | ||
| Percentage of payments received by Rexahn or its affiliates | 90.00% |
| X | ||||||||||
- Definition Contingent value right per each share of the Company's common stock held of record as of immediately prior to the closing of the merger. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Period for parent IP deal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Payment period for contingent value rights, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Percentage of payments received by Rexahn or its affiliates. No definition available.
|
| X | ||||||||||
- Definition Number of milestones had been accrued during the period. No definition available.
|
| X | ||||||||||
- Definition Number of potential milestones had been accrued during the period. No definition available.
|
| X | ||||||||||
- Definition Cash consideration paid by a third party to Rexahn or its affiliates during the applicable CVR payment period. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|